PPB PharmTech common mistakes
PPB PharmTech · Understand the traps and how to avoid them.
When asked to identify which changes to a registered product require a new marketing authorisation versus a variation, the candidate applies a generic rule (e.g., 'any change to the manufacturing site requires a new MA') without checking the jurisdiction's classification guidance or the specific type of change.
Candidates memorise broad categories from summaries instead of learning the actual variation classification system (e.g., major/minor, prior approval/notification) and the criteria for each. They also fail to distinguish between changes that affect the product's safety, efficacy, or quality profile and those that are administrative.
What to do instead
Study the official variation guidelines for the exam's jurisdiction and practise classifying real examples (e.g., change of excipient, change of batch size, change of site for a different dosage form). Create a decision tree that starts with the question: does the change affect the active substance, the manufacturing process, or only administrative details? Then map to the correct regulatory pathway.
In licensing questions, the candidate confuses the roles of the marketing authorisation holder (MAH), the manufacturer, the wholesaler, and the pharmacy, assuming that the MAH must hold a manufacturing licence or that a pharmacy automatically has a wholesale licence.
Candidates conflate legal entities and responsibilities because they study licensing in isolation from the supply chain. They also overlook that licensing requirements differ for physical persons versus legal persons and for different activities (manufacturing, import, distribution).
What to do instead
Map each actor to its licensed activities using a table: MAH (holds MA, responsible for pharmacovigilance and batch release), manufacturer (holds manufacturing licence), wholesaler (holds wholesale distribution licence), pharmacy (holds community pharmacy licence). For each, list what they may and may not do. Practise scenario questions where one entity performs multiple functions.
When answering Good Pharmacy Practice (GPP) questions, the candidate focuses only on dispensing accuracy and ignores broader GPP requirements such as premises, equipment, documentation, patient counselling, and the management of unlicensed medicines.
Candidates reduce GPP to 'right patient, right drug, right dose' and forget that GPP standards cover the entire pharmacy operation, including storage conditions, cold chain, waste disposal, and staff competence. They also miss that GPP applies to hospital and community settings differently.
What to do instead
Study the GPP guidelines section by section and for each section write a one-line summary of the required standard. Then practise questions that describe a pharmacy scenario and ask which GPP principle is breached. Pay special attention to areas like extemporaneous preparation, self-care, and public health services.
In CPD questions, the candidate treats CPD as equivalent to attending lectures or collecting certificates, and fails to recognise the cyclical process of reflection, planning, action, and evaluation, or the need to document learning outcomes.
Candidates rely on their own experience of continuing education, which may be input-based, and do not appreciate that CPD requires a personal record that demonstrates reflection and application to practice. They also confuse CPD with mandatory training.
What to do instead
Learn the CPD cycle as defined by the relevant pharmacy regulator (e.g., plan, act, reflect, record). For each stage, identify what evidence is required. Practise questions that give a CPD record and ask whether it meets the standard, or that ask what the pharmacist should do next in the cycle.
When answering regulatory inspection questions, the candidate lists inspection types (routine, for-cause, pre-approval) but cannot match the type to the trigger, the scope, or the outcome (e.g., inspection report, compliance rating, enforcement action).
Candidates memorise definitions without understanding the inspection lifecycle: planning, conduct, reporting, and follow-up. They also fail to distinguish between inspections of manufacturing sites, wholesalers, pharmacies, and clinical trial sites.
What to do instead
Create a matrix of inspection types versus triggers and outcomes. For each type, note who conducts it, what authority they have, what documents they can request, and what happens after (e.g., notice of deficiency, warning letter, licence suspension). Practise scenario questions where an inspector finds a specific deficiency and the candidate must identify the correct classification and follow-up.
In clinical trials questions, the candidate confuses the roles of the sponsor, investigator, ethics committee, and regulatory authority, and misapplies the requirements for informed consent, protocol amendments, and safety reporting.
Candidates study clinical trials as a list of documents (protocol, IB, ICF) without understanding the workflow and the responsibilities at each stage. They also overlook that requirements differ for different trial phases and for investigational products.
What to do instead
Map the clinical trial process from protocol development to close-out, and for each step list which party is responsible and what documentation is required. Focus on the approval chain: ethics committee approval, regulatory authorisation, and site initiation. Practise questions about protocol deviations, serious adverse event reporting timelines, and consent for vulnerable populations.
For market surveillance and control, the candidate assumes that post-marketing surveillance is limited to spontaneous reporting and does not consider other tools such as periodic safety update reports (PSURs), signal detection, risk management plans, and product recalls.
Candidates focus on the most visible activity (adverse event reporting) and neglect the broader surveillance system. They also fail to distinguish between the roles of the MAH, the regulator, and healthcare professionals in market surveillance.
What to do instead
Build a list of surveillance activities and for each note the responsible party, the trigger, and the output. Include: spontaneous reporting, PSUR, signal evaluation, risk minimisation measures, recalls, and batch testing. Practise questions that describe a safety signal and ask what action should be taken and by whom.
In pharmacovigilance questions, the candidate misclassifies adverse events (e.g., serious vs non-serious, expected vs unexpected) and applies incorrect reporting timelines, or fails to recognise the need for follow-up information.
Candidates memorise definitions but do not apply them to case narratives. They also confuse the reporting requirements for marketed products with those for clinical trials, and they forget that causality assessment is a separate step from seriousness.
What to do instead
Practise case classification using the official definitions: seriousness criteria (death, life-threatening, hospitalisation, disability, congenital anomaly, medically important), expectedness against the reference safety information, and causality (e.g., WHO-UMC scale). For each case, determine the report type (initial, follow-up, periodic) and the timeline. Use real case examples from training materials.
In quality control and lot release questions, the candidate confuses the roles of the manufacturer's QC laboratory, the national control laboratory (NCL), and the marketing authorisation holder, and misunderstands the concept of batch release certification (e.g., WHO prequalification, official batch release).
Candidates treat lot release as a single step and do not appreciate that it may involve testing by the manufacturer, review of manufacturing and testing records, and independent testing by an NCL for certain products (e.g., vaccines, blood products). They also overlook the difference between routine lot release and lot release for export.
What to do instead
Study the lot release system for the relevant jurisdiction: who performs testing, what documents are required (batch manufacturing record, certificate of analysis), and what constitutes a release decision. For products requiring official batch release, learn the timeline and the role of the NCL. Practise questions that give a batch record and ask whether it meets release criteria.
When using online systems and portals (e.g., for MA submission, adverse event reporting, or licensing), the candidate assumes that the portal is only a submission channel and ignores validation rules, data standards (e.g., HL7, ISO IDMP), and the need for user access management.
Candidates have limited hands-on experience with regulatory portals and study them theoretically. They also fail to recognise that portals enforce business rules (e.g., mandatory fields, format checks) and that errors can lead to rejection or delay.
What to do instead
Review the user guidance for the relevant portal (e.g., eCTD, national submission portal) and note the mandatory data elements, file formats, and validation checks. Practise with sample submissions or sandbox environments if available. For pharmacovigilance portals, learn the E2B reporting format and the minimum criteria for a valid case.